$0.07
(Market cap
$125 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
10.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-3.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.6
-
Face value
--
-
Shares outstanding
72,299,440
5 Years Aggregate
CFO
$-200.19 Mln
EBITDA
$-252.81 Mln
Net Profit
$-245.02 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biomea Fusion (BMEA)
| 50.8 | 59.8 | 34.5 | -4.1 | -52.2 | -33.7 | -- |
|
BSE Sensex
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Biomea Fusion (BMEA)
| -68.0 | -73.0 | 72.2 | 13.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Biomea Fusion (BMEA)
|
1.9 | 125.1 | 0.0 | -32.5 | -- | -156.1 | -- | 10.1 |
| 83.2 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 70.9 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 57.8 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 108.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 365.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 541.9 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 586.1 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 355.6 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.8 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Biomea Fusion (BMEA)
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and... COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California. Read more
-
Co-Founder, Chairman & CEO
Mr. Thomas Andrew Butler
-
Co-Founder, Chairman & CEO
Mr. Thomas Andrew Butler
-
Headquarters
San Carlos, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Biomea Fusion (BMEA)
What is the current share price of Biomea Fusion Inc (BMEA) Today?
The share price of Biomea Fusion Inc (BMEA) is $1.87 (NASDAQ) as of 02-Sep-2026 13:36 EDT. Biomea Fusion Inc (BMEA) has given a return of -52.21% in the last 3 years.
What is the current PB & PE ratio of Biomea Fusion Inc (BMEA)?
Since, TTM earnings of Biomea Fusion Inc (BMEA) is negative, P/E ratio is not available.
The P/B ratio of Biomea Fusion Inc (BMEA) is 10.06 times as on 28-Aug-2026, a 94 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.45 |
3.03 |
2024 |
-1.02 |
2.73 |
2023 |
-4.43 |
3.07 |
2022 |
-3.10 |
2.29 |
2021 |
-5.25 |
1.21 |
What is the 52 Week High and Low of Biomea Fusion Inc (BMEA)?
The 52-week high and low of Biomea Fusion Inc (BMEA) are Rs 2.99 and Rs 0.87 as of 03-Sep-2026.
What is the market cap of Biomea Fusion Inc (BMEA)?
Biomea Fusion Inc (BMEA) has a market capitalisation of $ 125 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Biomea Fusion Inc (BMEA)?
Before investing in Biomea Fusion Inc (BMEA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.